Edition:
United States

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

8.59CAD
2:19pm EDT
Change (% chg)

$-0.40 (-4.45%)
Prev Close
$8.99
Open
$9.00
Day's High
$9.13
Day's Low
$8.55
Volume
94,021
Avg. Vol
208,640
52-wk High
$14.75
52-wk Low
$4.96

Latest Key Developments (Source: Significant Developments)

European Medicines Agency Validates Marketing Authorization Application For Trogarzo
Friday, 14 Sep 2018 07:30am EDT 

Sept 14 (Reuters) - Theratechnologies Inc ::EUROPEAN MEDICINES AGENCY VALIDATES MARKETING AUTHORIZATION APPLICATION FOR TROGARZO.EMA WILL REVIEW APPLICATION FOR TROGARZO UNDER ACCELERATED ASSESSMENT PROCEDURE.SEEKS TO OBTAIN APPROVAL FOR TROGARZO FOR TREATMENT OF MULTIDRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS-1 IN EUROPEAN UNION.RELATED TO EMA CONFIRMING VALIDITY OF MARKETING AUTHORIZATION APPLICATION FOR TROGARZO, START OF PROCEDURE DATE BEEN SET TO SEPT 13.  Full Article

Theratechnologies Files Marketing Authorization Application For Trogarzo
Tuesday, 28 Aug 2018 07:38am EDT 

Aug 28 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES FILES MARKETING AUTHORIZATION APPLICATION FOR TROGARZO IN EUROPE.THERATECHNOLOGIES INC - EMA HAS UNTIL MID-SEPTEMBER TO CONFIRM WHETHER APPLICATION IS COMPLETE.  Full Article

Theratechnologies Reports Q4 Loss Per Share Of C$0.06
Wednesday, 7 Feb 2018 07:30am EST 

Feb 7 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017.Q4 REVENUE C$12.6 MILLION VERSUS C$10.38 MILLION.Q4 LOSS PER SHARE C$0.06.  Full Article

Theratechnologies Q3 loss per share c$0.04
Thursday, 5 Oct 2017 07:30am EDT 

Oct 5 (Reuters) - Theratechnologies Inc ::Theratechnologies announces financial results for third quarter of 2017.Q3 loss per share c$0.04.Q3 earnings per share view c$-0.03 -- Thomson Reuters I/B/E/S.Theratechnologies - ‍net sales revenue of Egrifta for fiscal 2017 is now expected to be in range of $42 million to $44 million​.  Full Article

Theratechnologies reports Q2 loss per share C$0.13
Wednesday, 12 Jul 2017 07:30am EDT 

July 12 (Reuters) - Theratechnologies Inc -:Theratechnologies announces financial results for second quarter of 2017.Q2 loss per share c$0.13.Q2 earnings per share view c$-0.03 -- Thomson Reuters I/B/E/S.Theratechnologies Inc - ‍no change in our previously reported guidance for 2017​.Theratechnologies Inc - ‍consolidated revenue for three-month ended May 31, 2017 was $10.016 million compared to $9.027 million.  Full Article

Theratechnologies says FDA sets PDUFA date of Jan 3 for ibalizumab application
Friday, 30 Jun 2017 01:19pm EDT 

June 30 (Reuters) - Theratechnologies Inc ::FDA grants priority review to HIV monoclonal antibody and long-acting investigational antiretroviral ibalizumab.FDA has set a prescription drug user fee act target action date of January 3, 2018, for ibalizumab application.  Full Article

Theratechnologies Q1 loss per share C$0.03
Thursday, 6 Apr 2017 07:30am EDT 

Theratechnologies Inc : Theratechnologies announces financial results for first quarter of 2017 . Q1 sales c$9.034 million . Q1 loss per share c$0.03 .Theratechnologies Inc - net sales revenue of Egrifta(®) for fy 17 is now expected to be in range of $44 million to $46 million (previously $40 million to $42 million).  Full Article

Theratechnologies Q1 loss per share C$0.03
Thursday, 6 Apr 2017 07:30am EDT 

Theratechnologies Inc : Theratechnologies announces financial results for first quarter of 2017 . Q1 sales C$9.034 million .Q1 loss per share C$0.03.  Full Article

Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territories
Monday, 6 Mar 2017 03:30am EST 

Theratechnologies Inc : Theratechnologies inc - agreement also includes upfront payment of US$3m payable through issuance of 906,077 common shares of Theratechnologies . Theratechnologies acquires commercial rights to Ibalizumab in the european union and four additional territories . Theratechnologies-Existing agreement between both companies has been amended to include additional territories and related new obligations . Theratechnologies inc -reached agreement with Taimed Biologics,for acquisition of commercial rights to Ibalizumab in European Union, Israel, Norway, Russia and Switzerland . Says under terms of agreement, Theratechnologies will assume regulatory responsibilities and associated costs . Theratechnologies inc - both parties have agreed to a transfer price of 52% for annual European sales up to us$50m .Says transfer price will increase to 57% on annual sales above us$50m threshold.  Full Article

Theratechnologies posts Q4 earnings per share C$0.00
Wednesday, 8 Feb 2017 07:30am EST 

Theratechnologies Inc : Theratechnologies announces financial results for fiscal year 2016 . Q4 revenue C$10.38 million versus I/B/E/S view c$9.6 million . Q4 earnings per share C$0.00 . Theratechnologies Inc - anticipate that FY net sales revenue will be in range of $40 million to $42 million .Theratechnologies -"we are now finalizing our plans for launch of ibalizumab in United States, which we believe will occur in 2017, if approved".  Full Article

BRIEF-Theratechnologies Says Reached Pricing Agreement With ADAP Crisis Task Force

* THERATECHNOLOGIES INC - REACHED A PRICING AGREEMENT WITH AIDS DRUG ASSISTANCE PROGRAM CRISIS TASK FORCE Source text for Eikon: Further company coverage: